Although the effects of IFN-α on myeloma are inconsistent, recent studies demonstrate that IFNs are critical in maintaining an effective antitumor response, and loss of IFN signaling results in resistance to treatment (13–15). This evidence concerns the gene IFNA1 and plasma cell myeloma.